Nomura Reaffirms Reduce Rating on AstraZeneca (AZN)
AstraZeneca (LON: AZN)‘s stock had its “reduce” rating restated by analysts at Nomura in a research report issued to clients and investors on Thursday. They currently have a $38.57 (2400 GBX) price target on the stock.
A number of other analysts have also recently weighed in on AZN. Analysts at Panmure Gordon & Co Limited reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Wednesday. They now have a $48.42 price target on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a $41.94 price target on the stock. Finally, analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Monday, September 10th. They now have a $48.32 price target on the stock.
Shares of AstraZeneca opened at 2910.50 on Thursday. AstraZeneca has a 52 week low of GBX 2578.50 and a 52 week high of GBX 3116.50. The company’s market cap is £36.643 billion.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.